查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016280

RNA干擾技術市場：2026-2032年全球市場預測（依分子類型、給藥途徑、遞送方式、應用及最終用戶分類）

RNA Interference Technology Market by Molecule Type, Route Of Administration, Delivery Method, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計RNA干擾技術市場在 2025 年的價值為 35.5 億美元，在 2026 年成長至 38.7 億美元，到 2032 年達到 65.1 億美元，複合年成長率為 9.05%。

主要市場統計數據
基準年 2025 35.5億美元
預計年份：2026年 38.7億美元
預測年份 2032 65.1億美元
複合年成長率 (%) 9.05%

建構RNA干擾技術創新和商業化的策略框架，同時考慮到治療方法開發和交付方面的挑戰以及監管趨勢。

RNA干擾（RNAi）已從實驗室研究發展成為臨床驗證有效的治療方法，對治療藥物開發和生物醫學研究產生了深遠的影響。過去十年，化學、遞送系統和監管環境的進步，使得早期概念驗證轉化為已通過核准的藥物，並拓展了涵蓋多種適應症的候選藥物研發管線。因此，決策者必須認知到RNAi獨特的技術限制和機遇，同時將其置於更廣泛的創新框架中，該框架還包括互補的基因編輯和寡核苷酸療法。

從遞送平台到臨床療效驗證，甚至跨模式整合，快速的技術和監管變革正在重新定義RNA干擾療法。

在技​​術創新、監管先例和生態系統融合的共同推動下， RNA干擾領域正經歷著一場變革性的轉變。結合化學和標靶遞送機制的突破顯著提高了治療指數和組織特異性，使以往難以應用的適應症得以實現。同時，平台技術的成熟推動了模組化開發模式的形成，使得遞送載體等單一要素的最佳化能夠在多個專案中重複使用，從而提高研發效率並降低專案風險。

本報告預測了美國在 2025 年實施的關稅政策對全球 RNAi 供應鏈、採購和研究營運的累積影響。

美國2025年實施的累積關稅措施凸顯了全球生命科學供應鏈的戰略脆弱性，為RNAi研發人員和供應商帶來了新的成本和營運壓力。由於關稅導致進口試劑、特殊脂質和某些設備組件的到貨成本增加，促使各方重新評估籌資策略和多源採購計劃。這迫使各機構加快替代供應商的認證，優先考慮與國內製造夥伴關係，並重新評估庫存管理實踐，以確保專案進度。

RNAi 生態系統按分子類別、遞送方法、給藥途徑、應用領域和最終用戶角色進行細分，以明確策略重點。

對RNAi生態系進行有意義的細分，有助於明確科研努力與商業性機會的契合點。基於分子類型，市場研究已對微型RNA（miRNA）、短髮夾RNA（shRNA）和小干擾RNA（siRNA）進行了考察，並進一步將短髮夾RNA細分為非病毒載體shRNA和病毒載體shRNA，將小干擾RNA細分為偶聯siRNA和非偶聯siRNA。這種分子層次的分類揭示了不同的技術和調控途徑。 miRNA方法通常針對調控特定通路，而shRNA構建體通常能夠實現持續的基因敲低，其持久性取決於載體的選擇。另一方面，siRNA計畫則傾向於優先考慮化學穩定性以及與標靶的結合，以實現精準遞送。

影響美洲、歐洲、中東和非洲以及亞太地區 RNAi 開發和商業化的區域趨勢及其明顯的營運影響。

區域趨勢顯著影響RNAi計畫從發現到臨床應用的進程。在美洲，對生物技術企業的大力投資、先進的臨床試驗基礎設施以及對監管法規的熟悉程度，共同推動了平台創新快速應用於人體標靶研究。該地區還聚集了大量的合約開發商和專業供應商，使其成為後期工藝放大和商業化生產夥伴關係的理想之地。

透過競爭與合作並存的企業行為，RNAi 創新受到策略聯盟、與 CDMO 的合作以及智慧財產權策略的影響。

RNAi領域的企業行為呈現出平台專業化、策略夥伴關係以及與合約研發生產機構（CDMO）加強協作的混合特徵。技術主導公司專注於創新化學和遞送技術，以便將其授權應用於多個專案；而多元化的生物製藥公司則致力於針對高優先適應症進行內部研發，並在能夠利用互補專長的領域中進行選擇性合作，從而加速研發進程。同時，契約製造和服務供應商也不斷提升自身能力，以應對寡核苷酸療法的複雜性和監管要求，從而建構一個更模組化的生態系統。

產業領導者可透過投資遞送技術、監管合規和供應鏈韌性來加速RNAi專案的成功，並可採取以下策略行動

產業領導者應制定切實可行的優先事項，將RNAi的潛力轉化為永續的臨床和商業性成果。首先，他們應認知到早期遞送方法的選擇對安全性、有效性和可擴展性有顯著影響，並應投資於與目標組織和臨床目標相符的遞送平台的能力。其次，他們應制定供應鏈彈性計劃，包括選擇經認證的替代供應商、區域生產方案和庫存策略，以降低關稅和地緣政治動盪的影響。第三，他們應儘早與監管機構進行頻繁對話，並利用預提交會議和適應性試驗設計，使安全性監測和終點選擇與支付方的預期保持一致。

透過高度透明和嚴謹的調查方法檢驗對 RNAi 的策略見解，該方法結合了與專家的對話、第二手資料的整合和檢驗。

本研究採用嚴謹的混合方法，結合了專家訪談的初步質性研究和對公開科學及監管資料的結構化二次整合。初步研究包括對臨床醫生、藥物科學家、監管顧問和生產專家的訪談，以了解實際限制和短期營運的考量。透過這些對話，我們提出了關於給藥途徑權衡、特定途徑的安全考量以及區域推廣障礙的假設。

關於RNAi研發中策略挑戰的結論：科學、實施和政策的整合將影響臨床療效

總之， RNA干擾正處於一個策略轉折點，持續的科學進步、監管政策的明確性以及商業性利益在此交匯，拓展了其治療潛力。遞送化學和平台最佳化的進步正在開拓需要精準組織標靶化的潛在適應症，而監管先例也消除了專案開發中一些過去的不確定性。然而，營運和策略的複雜性也在增加。供應鏈趨勢、地緣政治因素以及證明實際價值的需求，都要求藥物發現、開發和商業化等各環節進行整合規劃。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：以分子類型分類的RNA干擾技術市場

  • 微型RNA（miRNA）
  • 短髮夾RNA（shRNA）
    • 非病毒載體shRNA
    • 病毒傳播的shRNA
  • 小干擾RNA（siRNA）
    • 偶聯siRNA
    • 未結合的siRNA

第9章： RNA干擾技術市場：依給藥途徑分類

  • 肌肉內注射
  • 鞘內（IT）給藥
  • 靜脈注射

第10章： RNA干擾技術市場：依遞送方式分類

  • 直接遞送裸露的RNAi
  • 以外泌體為基礎的RNAi療法
  • 利用奈米顆粒進行遞送
  • 利用病毒載體進行遞送

第11章RNA干擾技術市場：依應用領域分類

  • 藥物發現
    • 先導藥物最適化
    • 目標識別
  • 研究與開發
    • 基因功能研究
    • 訊號傳導通路分析
  • 治療藥物

第12章RNA干擾技術市場：依最終用戶分類

  • 合約研究機構
  • 醫院和診所
  • 製藥和生物技術公司

第13章RNA干擾技術市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章RNA干擾技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章RNA干擾技術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國RNA干擾技術市場

第17章：中國RNA干擾技術市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alnylam Pharmaceuticals, Inc.
  • AMSBIO
  • Arbutus Biopharma Corporation
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Atalanta Therapeutics
  • Bioneer Corporation
  • Dicerna Pharmaceuticals, Inc.
  • Gradalis, Inc.
  • Horizon Therapeutics plc
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Novartis AG
  • Nutcracker Therapeutics, Inc.
  • Phio Pharmaceuticals Corp.
  • ProQR Therapeutics NV
  • Sanofi SA
  • Silence Therapeutics PLC
  • Sirnaomics, Inc.
  • Thermo Fisher Scientific Inc.
  • Vir Biotechnology, Inc.
Product Code: MRR-0375F3EAA810

The RNA Interference Technology Market was valued at USD 3.55 billion in 2025 and is projected to grow to USD 3.87 billion in 2026, with a CAGR of 9.05%, reaching USD 6.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.55 billion
Estimated Year [2026] USD 3.87 billion
Forecast Year [2032] USD 6.51 billion
CAGR (%) 9.05%

Setting the strategic context for RNA interference innovation and commercialization across therapeutic development, delivery challenges, and regulatory momentum

RNA interference (RNAi) has matured from a laboratory phenomenon into a clinically validated modality with durable implications for therapeutic development and biomedical research. Over the past decade, advances in chemistry, delivery systems, and regulatory clarity have converted early proofs of concept into approved drugs and a growing pipeline of candidates across multiple indications. As a result, decision-makers must situate RNAi within a broader innovation landscape that includes complementary gene editing and oligonucleotide approaches while recognizing unique technical constraints and opportunity windows.

This executive-level introduction frames RNAi as both a scientific platform and a commercial proposition. It highlights how improvements in stability, targeting, and manufacturing have reduced historical barriers while the ongoing evolution of delivery technologies-ranging from conjugates to nanoparticles to viral vectors-creates differentiated pathways for clinical translation. Finally, this section underscores the importance of integrating regulatory strategy, payer considerations, and downstream manufacturing readiness early in program design in order to de-risk development and accelerate time to meaningful patient impact.

Rapid technological and regulatory shifts redefining RNA interference therapeutics from delivery platforms to clinical validation and cross-modal integration

The landscape for RNA interference is undergoing transformative shifts driven by technical innovation, regulatory precedent, and ecosystem convergence. Breakthroughs in conjugation chemistry and targeted delivery mechanisms have materially improved therapeutic index and tissue specificity, enabling indications that were previously out of reach. Concurrently, the maturation of platform know-how is facilitating modular development approaches where optimization of one element-such as a delivery vehicle-can be reused across multiple programs, thereby increasing R&D efficiency and lowering program risk.

Regulatory agencies have also moved from conceptual guidance to more concrete review pathways, reducing uncertainty and enabling clearer development milestones. At the same time, cross-modal integration with complementary technologies such as gene editing and mRNA therapeutics is creating hybrid strategies that combine durable knockdown with editing or transient expression, expanding the scope of treatable diseases. Market dynamics reflect increased collaboration between platform developers, contract manufacturers, and clinical partners, which accelerates translation but also requires more sophisticated alliance management and IP strategies. Taken together, these shifts are reorienting investment and operational priorities toward scalable delivery, regulatory alignment, and strategic partnerships.

Anticipating the cumulative impact of United States tariff policies enacted in 2025 on global RNAi supply chains, sourcing, and research operations

The introduction of cumulative tariff measures by the United States in 2025 has emphasized the strategic fragility of global life sciences supply chains and highlighted new cost and operational pressures for RNAi developers and suppliers. Tariff-related increases in the landed cost of imported reagents, specialized lipids, and certain device components have triggered a reassessment of sourcing strategies and multi-sourcing plans. This has encouraged organizations to accelerate qualification of alternative suppliers, prioritize domestic manufacturing partnerships, and re-evaluate inventory management practices to preserve program timelines.

Consequently, companies are recalibrating their outsourcing models to reduce exposure to tariff volatility, increasing interest in regional contract manufacturing capacity, and reexamining the total cost of ownership for critical raw materials. In parallel, procurement and legal teams are working more closely with R&D to identify tariff-sensitive inputs early in development so that formulation design and process choices can mitigate exposure. From a strategic perspective, the tariffs have underscored the value of supply chain transparency, pre-competitive consortia for critical component production, and contingency planning that preserves clinical momentum while managing incremental cost pressures.

Segmenting the RNAi ecosystem by molecule class, delivery approach, administration route, application focus, and end-user roles to reveal strategic priorities

Meaningful segmentation of the RNAi ecosystem clarifies where scientific effort and commercial opportunity align. Based on Molecule Type, market studies consider MicroRNA (miRNA), Short Hairpin RNA (shRNA), and Small Interfering RNA (siRNA), with Short Hairpin RNA further examined across Non-Viral Delivery shRNA and Viral Delivery shRNA and Small Interfering RNA further analyzed as Conjugated siRNA and Non-Conjugated siRNA. This molecular stratification reveals distinct technical and regulatory pathways: miRNA approaches frequently target pathway modulation, shRNA constructs often enable durable knockdown with vector choices dictating persistence, and siRNA programs tend to emphasize chemical stabilization and targeted conjugation for precision delivery.

Based on Route Of Administration, the ecosystem is studied across Intramuscular (IM) Injection, Intrathecal (IT) Administration, and Intravenous (IV) Injection, each of which imposes different formulation, safety monitoring, and clinical trial design requirements. Based on Delivery Method, the field is appraised across Direct Naked RNAi Delivery, Exosome-Based RNAi Therapy, Nanoparticle-Based Delivery, and Viral Vector-Based Delivery, highlighting how payload, target tissue, and immunogenicity considerations drive modality selection. Based on Application, the landscape spans Drug Discovery, Research & Development, and Therapeutics, with Drug Discovery further broken down into Lead Optimization and Target Identification and Research & Development further divided into Gene Function Studies and Pathway Analysis. Finally, based on End-User, stakeholders include Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies, each engaging with RNAi capabilities at different points in the value chain. Synthesizing these segmentation dimensions enables program teams to prioritize technical investments, align clinical strategy with administration routes, and select partners whose capabilities match the intended product profile.

Regional dynamics shaping RNAi development and commercialization across the Americas, Europe Middle East & Africa, and Asia-Pacific with distinct operational implications

Regional dynamics significantly influence how RNAi programs progress from discovery into clinical application. In the Americas, a combination of strong biotechnology venture investment, advanced clinical trial infrastructure, and regulatory familiarity has supported rapid translation of platform innovations into human studies. This geography also hosts a dense concentration of contract developers and specialized suppliers, making it an attractive location for late-stage process scale-up and commercial manufacturing partnerships.

In Europe, Middle East & Africa, regulatory harmonization across major markets and robust academic hubs drive translational science, while national centers of excellence contribute specialized capabilities in formulation and vector engineering. Market access pathways and payer negotiation dynamics in Europe require earlier demonstration of real-world outcomes and companion diagnostics in certain therapeutic areas. The Asia-Pacific region combines large patient populations for clinical enrollment, rapidly expanding biomanufacturing capacity, and active government initiatives to support biotechnology infrastructure. Taken together, these regional distinctions shape strategic choices about where to site clinical trials, manufacture drug product, and cultivate long-term partnerships based on regulatory environment, cost base, and talent availability.

Competitive and collaborative company behaviors shaping RNAi innovation through strategic partnerships, CDMO engagement, and intellectual property strategies

Company behavior in the RNAi domain is characterized by a mix of platform specialization, strategic partnerships, and increasing engagement with contract development and manufacturing organizations. Technology-focused firms concentrate on chemistry and delivery innovations that can be licensed across multiple programs, while diversified biopharma firms pursue in-house development for high-priority indications and selectively partner where complementary expertise accelerates timelines. At the same time, contract manufacturers and service providers are expanding capabilities to address formulation complexity and regulatory expectations for oligonucleotide therapies, creating a more modular ecosystem.

Competitive differentiation increasingly rests on the depth of delivery know-how, the strength and clarity of intellectual property portfolios, and the ability to execute late-stage manufacturing reliably. Partnerships and licensing deals remain common mechanisms to combine discovery-stage innovation with commercial-scale capabilities. Additionally, vertical integration is emerging as a strategic option for organizations seeking to control critical supply chain nodes, although this approach requires significant capital and operational sophistication. For emerging companies, judicious collaboration with experienced clinical development and manufacturing partners reduces execution risk and accelerates the path from concept to clinic.

Strategic actions for industry leaders to accelerate RNAi program success through delivery investment, regulatory alignment, and supply chain resilience

Industry leaders should adopt a set of actionable priorities to translate RNAi potential into durable clinical and commercial outcomes. First, invest in delivery platform capabilities that match target tissues and clinical objectives, recognizing that delivery choices made during early development materially affect safety, efficacy, and scalability. Second, develop supply chain resilience plans that include qualified alternate suppliers, regional manufacturing options, and inventory strategies to mitigate tariff and geopolitical disruption. Third, pursue regulatory engagement early and often, using pre-submission meetings and adaptive trial designs to align safety monitoring and endpoint selection with payer expectations.

Moreover, leaders should pursue strategic partnerships with contract development and manufacturing organizations to de-risk scale-up while retaining optionality for manufacturing ownership in the future. They should also prioritize data interoperability and real-world evidence collection to support both regulatory submissions and payer value demonstration. Finally, invest in talent and governance structures that enable rapid learning across platforms-creating cross-functional teams that bridge discovery chemistry, translational pharmacology, clinical development, and commercial strategy to accelerate decision-making and program progress.

Transparent and rigorous research methodology combining expert engagement, secondary synthesis, and triangulation to validate RNAi strategic insights

This research employs a rigorous mixed-methods approach combining primary qualitative engagement with subject-matter experts and structured secondary synthesis of public scientific and regulatory sources. Primary research included interviews with clinicians, formulation scientists, regulatory advisors, and manufacturing specialists to capture practical constraints and near-term operational considerations. These conversations informed hypothesis generation around delivery trade-offs, route-specific safety considerations, and regional implementation barriers.

Secondary research synthesized peer-reviewed literature, clinical trial registries, regulatory guidance documents, and company disclosures to contextualize primary insights and validate technical assertions. Data triangulation ensured that conclusions reflected convergent evidence rather than single-source assumptions, and quality checks included cross-validation of technical details with independently published protocols and regulatory filings. The methodology also accounted for limitations, noting areas where data remain emergent-such as long-term real-world safety for new delivery modalities-and recommending targeted follow-up studies to address these gaps.

Concluding perspectives on the strategic imperatives for RNAi development as science, delivery, and policy converge to shape clinical impact

In summary, RNA interference stands at a strategic inflection point where sustained scientific progress, evolving regulatory clarity, and commercial interest converge to expand therapeutic potential. Progress in delivery chemistry and platform optimization is unlocking indications that require precise tissue targeting, while regulatory precedents reduce some historical uncertainty for program development. Nevertheless, operational and strategic complexity has increased: supply chain dynamics, geopolitical considerations, and the imperative to demonstrate real-world value demand integrated planning across discovery, development, and commercialization functions.

Organizations that succeed will be those that harmonize scientific ambition with pragmatic operational execution-investing early in delivery solutions, diversifying sourcing and manufacturing strategies, engaging regulators proactively, and forming targeted partnerships to access missing capabilities. By aligning technical design choices with clinical and commercial constraints, program teams can accelerate translation while preserving flexibility to adapt to emerging data and market signals. The path forward requires disciplined program design, robust external collaboration, and sustained investment in the capabilities that convert molecular promise into patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Interference Technology Market, by Molecule Type

  • 8.1. MicroRNA (miRNA)
  • 8.2. Short Hairpin RNA (shRNA)
    • 8.2.1. Non-Viral Delivery shRNA
    • 8.2.2. Viral Delivery shRNA
  • 8.3. Small Interfering RNA (siRNA)
    • 8.3.1. Conjugated siRNA
    • 8.3.2. Non-Conjugated siRNA

9. RNA Interference Technology Market, by Route Of Administration

  • 9.1. Intramuscular (IM) Injection
  • 9.2. Intrathecal (IT) Administration
  • 9.3. Intravenous (IV) Injection

10. RNA Interference Technology Market, by Delivery Method

  • 10.1. Direct Naked RNAi Delivery
  • 10.2. Exosome-Based RNAi Therapy
  • 10.3. Nanoparticle-Based Delivery
  • 10.4. Viral Vector-Based Delivery

11. RNA Interference Technology Market, by Application

  • 11.1. Drug Discovery
    • 11.1.1. Lead Optimization
    • 11.1.2. Target Identification
  • 11.2. Research & Development
    • 11.2.1. Gene Function Studies
    • 11.2.2. Pathway Analysis
  • 11.3. Therapeutics

12. RNA Interference Technology Market, by End-User

  • 12.1. Contract Research Organizations
  • 12.2. Hospitals & Clinics
  • 12.3. Pharmaceutical & Biotechnology Companies

13. RNA Interference Technology Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. RNA Interference Technology Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. RNA Interference Technology Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States RNA Interference Technology Market

17. China RNA Interference Technology Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alnylam Pharmaceuticals, Inc.
  • 18.6. AMSBIO
  • 18.7. Arbutus Biopharma Corporation
  • 18.8. Arcturus Therapeutics Holdings Inc.
  • 18.9. Arrowhead Pharmaceuticals, Inc.
  • 18.10. Atalanta Therapeutics
  • 18.11. Bioneer Corporation
  • 18.12. Dicerna Pharmaceuticals, Inc.
  • 18.13. Gradalis, Inc.
  • 18.14. Horizon Therapeutics plc
  • 18.15. Ionis Pharmaceuticals, Inc.
  • 18.16. Merck KGaA
  • 18.17. Novartis AG
  • 18.18. Nutcracker Therapeutics, Inc.
  • 18.19. Phio Pharmaceuticals Corp.
  • 18.20. ProQR Therapeutics N.V.
  • 18.21. Sanofi S.A.
  • 18.22. Silence Therapeutics PLC
  • 18.23. Sirnaomics, Inc.
  • 18.24. Thermo Fisher Scientific Inc.
  • 18.25. Vir Biotechnology, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 178. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 179. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 184. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 198. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 199. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 208. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 209. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 211. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 214. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 218. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 219. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 221. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 224. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 239. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 240. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)